For years, the HPV vaccine was framed primarily as protection against cervical cancer. Findings presented at the American Society of Clinical Oncology annual meeting are now challenging that framing with some of the most compelling real-world evidence yet: among more than a million people tracked in a large U.S. cohort, vaccinated men developed roughly half as many HPV-related cancers as unvaccinated men. The numbers were 26 cancers in the vaccinated group versus 57 in the unvaccinated group, a gap researchers called statistically significant even at these still-modest absolute counts.
The results land at a moment when HPV-driven cancers in men, particularly oropharyngeal cancers that form in the throat, base of the tongue, and tonsils, are rising faster than almost any other malignancy in the United States.
What the ASCO data actually show
The cohort study tracked cancer outcomes in vaccinated and unvaccinated men over a period long enough for HPV-driven tumors to begin appearing in the first generation of males eligible for the vaccine. The 57-to-26 cancer gap is the central finding, and oropharyngeal cancer accounts for the largest share of that difference. That pattern matches what federal cancer surveillance has documented for years: oropharyngeal tumors are now the most common HPV-associated cancer in American men, surpassing all other HPV-linked malignancies combined.
The biological logic connecting vaccination to fewer throat cancers is well established. Research led by Anil Chaturvedi and colleagues at the National Cancer Institute’s Division of Cancer Epidemiology and Genetics found that vaccinated individuals carried significantly lower rates of oral HPV infection, the persistent infection that precedes oropharyngeal cancer by years or decades. Block the infection early, and the cancer never gets its start.
The relatively small absolute numbers reflect biology, not weakness in the data. HPV-related cancers typically take 20 to 30 years to develop. The first cohorts of vaccinated boys are only now entering their late 20s and 30s, meaning the full cancer-prevention impact will not be visible for another decade or more. What makes the ASCO findings notable is that a measurable difference is already showing up this early.
Where the evidence stands on policy
The Advisory Committee on Immunization Practices has recommended the 9-valent HPV vaccine (Gardasil 9) for boys and young men since 2011, with updated guidance in 2015 confirming the newer formulation’s strong immune response and expanded strain coverage. The FDA approved the vaccine for males, and ongoing monitoring through the Vaccine Adverse Event Reporting System has not raised new safety concerns.
The practical question now is not whether boys should be vaccinated. That question was settled years ago. The question is whether enough of them are getting vaccinated to bend the cancer curve at a population level. HPV vaccination completion rates among adolescent males, while improving, still lag behind rates for other routine adolescent vaccines. A peer-reviewed modeling study by Brisson et al., published in The Lancet Public Health, projected that the long-term reduction in male oropharyngeal cancers depends heavily on how many boys complete the vaccine series, and that pandemic-era disruptions to routine adolescent vaccination could delay progress further.
What remains uncertain
The ASCO findings come from an observational cohort, not a randomized controlled trial. That distinction matters. Men who chose vaccination may differ from those who did not in ways that independently affect cancer risk: they may have better access to healthcare, lower smoking rates, or different sexual behavior patterns. Researchers adjusted for known confounders, but observational designs cannot eliminate all of them. The full methodology has not yet appeared in a peer-reviewed journal, so independent scrutiny of the statistical approach is still pending.
It is also worth noting that 26 HPV-related cancers still occurred among vaccinated men. The vaccine targets nine HPV strains responsible for the vast majority of HPV-driven cancers, but it does not cover every strain. Co-factors like tobacco use, heavy alcohol consumption, and compromised immune function can also contribute to malignancy. Vaccination sharply reduces risk. It does not eliminate it.
No official statement from ACIP or the FDA has indicated whether the ASCO data will prompt changes to existing guidance. The current recommendations already cover males ages 9 through 26, so the more likely shift would be in public health messaging rather than eligibility. Framing the vaccine as cancer prevention for men, not just women, could help close the uptake gap that worries epidemiologists.
Why a randomized trial is unlikely, and why that is acceptable
Some critics argue that definitive proof requires a randomized trial with cancer as the endpoint. In practice, that trial will almost certainly never happen, and not because the science is weak. HPV-related cancers take decades to develop, which would require extraordinarily long follow-up. More importantly, withholding a vaccine with strong evidence of benefit from a control group would raise serious ethical problems, particularly after randomized trials in women already demonstrated the vaccine’s ability to prevent precancerous lesions caused by the same viral strains.
Regulators and advisory committees instead relied on a chain of evidence: immune response data, infection-reduction studies, precancerous lesion trials in women, and now real-world cancer outcome data in men. Each link reinforces the others. The ASCO cohort adds the final piece that was previously missing: actual cancer diagnoses, tracked in a large population, showing fewer tumors in vaccinated men.
What this means for parents and young adults weighing vaccination in 2026
The ACIP recommendation covers the 9-valent HPV vaccine for males starting at age 9, with catch-up vaccination available through age 26. The vaccine series is most effective when completed before exposure to HPV, which typically occurs soon after sexual debut. For adolescents, that means the ideal window is ages 11 to 12, when the immune response is strongest and two doses (rather than three) complete the series.
For young men in their late teens or early 20s who missed the recommended schedule, catch-up vaccination still offers meaningful protection. Clinicians note that even partial-series vaccination provides some immune benefit, though completing all recommended doses maximizes it. Men older than 26 fall outside the routine ACIP recommendation, though shared clinical decision-making with a healthcare provider is an option for adults ages 27 through 45 under existing FDA approval of Gardasil 9 for that age range.
The ASCO data sharpen a message that oncologists and public health officials have been pushing for years: HPV vaccination is not a women’s health intervention with a male add-on. It is cancer prevention, full stop. Throat cancer is now the most common HPV-driven malignancy in American men, and the new findings suggest the vaccine works against it in the real world, not just in theory. As the vaccinated generation ages and more follow-up data accumulate, researchers expect the evidence to grow only stronger. For families making decisions about adolescent vaccination in spring 2026, the case for completing the HPV series on schedule has never been clearer.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
